Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Personalized preventive care aims to cut deaths by 20% in low-income communities

NCT ID NCT05828849

Disease control Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a personalized program—including patient navigation, individual health benefits, and financial help—can reduce deaths from preventable causes like heart attacks, strokes, heavy drinking, and HIV in low-income adults aged 35–64. Researchers will track changes in alcohol use, HIV risk, and heart disease risk over 12 months. The goal is to see if this approach can lower mortality by 20% in this high-risk group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

87 people

The number who actually took part.

Started

Jun 2024

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 to 64 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 35 to 64 2. Low SES (≤ $38,000 annual income, based on 2019 20th percentile NYC income, adjusted for family size) 3. Expected mortality ≥1% per year (based on age, sex, race/ethnicity), with ≥1 of the following contributors: 1. 10-year cardiovascular risk ≥10% (assessed by ASCVD risk tool) 2. Heavy alcohol consumption (defined using SAMHSA binge drinking definition, drinking \>4 standard drinks for men and \>3 standard drinks for women on same occasion in past month) 4. Willing to be navigated to Health and Hospitals Corporation of New York health system. 5. Ability to provide written informed consent in English or Spanish Exclusion Criteria: 1. Receives regular care elsewhere than Health and Hospitals Corporation of New York 2. Already diagnosed with high mortality-condition(s) that are not included in the simulation model.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alcohol use disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alcohol abuse cardiovascular disorder substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alcohol use disorder Cardiovascular disease HIV risk Substance use disorders

Contacts and locations

Locations

  • NYC H+H/Bellevue

    New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.